PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
EBIT growth below 50% of TRAW's 49.83%. Michael Burry would suspect deeper competitive or cost structure issues.
10.76%
Operating income growth under 50% of TRAW's 49.83%. Michael Burry would be concerned about deeper cost or sales issues.
11.35%
Net income growth under 50% of TRAW's 53.14%. Michael Burry would suspect the firm is falling well behind a key competitor.
31.03%
EPS growth at 50-75% of TRAW's 53.59%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
31.72%
Diluted EPS growth at 50-75% of TRAW's 53.59%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
29.31%
Share count expansion well above TRAW's 0.99%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
29.44%
Diluted share count expanding well above TRAW's 0.99%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
2.31%
OCF growth under 50% of TRAW's 25.63%. Michael Burry might suspect questionable revenue recognition or rising costs.
3.06%
FCF growth under 50% of TRAW's 25.63%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
Negative 10Y OCF/share CAGR while TRAW stands at 98.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
64.50%
5Y OCF/share CAGR at 50-75% of TRAW's 99.15%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
73.57%
3Y OCF/share CAGR at 75-90% of TRAW's 96.25%. Bill Ackman would press for improvements in margin or overhead to catch up.
-9976.84%
Negative 10Y net income/share CAGR while TRAW is at 99.17%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-124.34%
Negative 5Y net income/share CAGR while TRAW is 99.48%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
76.73%
3Y net income/share CAGR 75-90% of TRAW's 97.97%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1493.31%
Equity/share CAGR of 1493.31% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-38.28%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-74.77%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Positive asset growth while TRAW is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
127.26%
Positive BV/share change while TRAW is negative. John Neff sees a clear edge over a competitor losing equity.
-9.95%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.53%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-21.01%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.